WALTHAM, Mass. / Oct 30, 2023 / Business Wire / Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
“QINLOCK achieved another record quarter of product revenue with continued strength in commercial demand,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “With the positive results of the MOTION Phase 3 study of vimseltinib we reported earlier today, we are now one step closer to becoming a company with multiple approved products. We look forward to engaging with regulatory authorities to advance vimseltinib toward approval and deliver it to the TGCT patients in need of an effective and well tolerated treatment option."
Third Quarter 2023 Highlights and Upcoming Milestones
QINLOCK® (ripretinib)
Vimseltinib
DCC-3116
DCC-3084
DCC-3009
Third Quarter 2023 Financial Results
Conference Call and Webcast
Deciphera will host a conference call and webcast to discuss this announcement today, October 30, 2023, at 8:00 AM ET. The conference call may be accessed via this link.. A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors & News” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding the potential for our preclinical and/or clinical stage pipeline assets to be first-in-class and/or best-in-class treatments; our Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18; the potential for vimseltinib to become our second approved medicine, plans to submit an NDA for vimseltinib in the second quarter of 2024 and an MAA in the third quarter of 2024, and plans to present additional data at upcoming medical congresses; plans for our ongoing Phase 1/2 studies of DCC-3116; plans to submit an IND application to the FDA for DCC-3084 by the end of 2023; plans to submit an IND application to the FDA for DCC-3009 in the first half of 2024; and cash guidance. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
The Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks and Deciphera is a trademark of Deciphera Pharmaceuticals, LLC.
Deciphera Pharmaceuticals, Inc. | |||
Consolidated Balance Sheets | |||
(Unaudited, in thousands, except share and per share amounts) | |||
| September 30, |
| December 31, |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents | $108,087 |
| $64,741 |
Short-term marketable securities | 230,988 |
| 259,745 |
Accounts receivable, net | 27,549 |
| 22,429 |
Inventory | 27,105 |
| 20,561 |
Prepaid expenses and other current assets | 23,847 |
| 25,482 |
Total current assets | 417,576 |
| 392,958 |
Long-term marketable securities | 37,850 |
| 14,550 |
Long-term investments—restricted and other long-term assets | 3,337 |
| 3,277 |
Property and equipment, net | 5,864 |
| 6,707 |
Operating lease assets | 33,209 |
| 36,547 |
Total assets | $497,836 |
| $454,039 |
Liabilities and Stockholders' Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable | $21,453 |
| $18,612 |
Accrued expenses and other current liabilities | 68,005 |
| 64,622 |
Operating lease liabilities | 3,436 |
| 3,235 |
Total current liabilities | 92,894 |
| 86,469 |
Operating lease liabilities, net of current portion | 23,272 |
| 25,879 |
Total liabilities | 116,166 |
| 112,348 |
Commitments and contingencies |
|
|
|
Stockholders' equity: |
|
|
|
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding | — |
| — |
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 79,975,625 shares and 67,637,351 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 799 |
| 676 |
Additional paid-in capital | 1,762,882 |
| 1,575,361 |
Accumulated other comprehensive income (loss) | (896) |
| (983) |
Accumulated deficit | (1,381,115) |
| (1,233,363) |
Total stockholders' equity | 381,670 |
| 341,691 |
Total liabilities and stockholders' equity | $497,836 |
| $454,039 |
|
|
|
|
Deciphera Pharmaceuticals, Inc. | |||||||
Consolidated Statements of Operations | |||||||
(Unaudited, in thousands, except share and per share amounts) | |||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||
| 2023 | 2022 | 2023 | 2022 | |||
Revenues: |
|
|
|
| |||
Product revenues, net | $41,820 | $32,318 | $112,362 | $92,624 | |||
Collaboration revenues | 1,493 | 3,656 | 2,700 | 5,067 | |||
Total revenues | 43,313 | 35,974 | 115,062 | 97,691 | |||
Cost and operating expenses: |
|
|
|
| |||
Cost of sales | 1,286 | 3,344 | 1,947 | 5,525 | |||
Research and development | 62,463 | 47,485 | 175,524 | 139,755 | |||
Selling, general, and administrative | 33,252 | 30,026 | 97,311 | 87,972 | |||
Total cost and operating expenses | 97,001 | 80,855 | 274,782 | 233,252 | |||
Loss from operations | (53,688) | (44,881) | (159,720) | (135,561) | |||
Other income (expense): |
|
|
|
| |||
Interest and other income, net | 4,107 | 1,838 | 11,968 | 2,565 | |||
Total other income (expense), net | 4,107 | 1,838 | 11,968 | 2,565 | |||
Net loss | $(49,581) | $(43,043) | $(147,752) | $(132,996) | |||
|
|
|
|
| |||
Net loss per share—basic and diluted | $(0.58) | $(0.55) | $(1.75) | $(1.82) | |||
Weighted average common shares outstanding—basic and diluted | 85,788,613 | 78,206,647 | 84,506,593 | 73,129,804 |
Last Trade: | US$25.51 |
Daily Change: | 0.01 0.04 |
Daily Volume: | 549,775 |
Market Cap: | US$2.210B |
April 09, 2024 February 06, 2024 February 01, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB